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While rare compared to female breast cancer the incidence of male breast cancer (MBC) has increased in the last
few decades. Without comprehensive epidemiological studies, the explanation for the increased incidence of MBC
can only be speculated. Nevertheless, one of the most worrying global public health issues is the exponential rise
in the number of overweight and obese people, especially in the developed world. Although obesity is not considered
an established risk factor for MBC, studies have shown increased incidence among obese individuals. With this
observation in mind, this article highlights the correlation between the increased incidence of MBC and the
current trends in obesity as a growing problem in the 21st century, including how this may impact treatment.
With MBC becoming more prominent we put forward the notion that, not only is obesity a risk factor for MBC,
but that increasing obesity trends are a contributing factor to its increased incidence.
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To our knowledge, male breast cancer (MBC) was first
reported in the medical literature in 1843 and described
as the cause of death of five men in Paris from 1830 to
1840 [1]. Starting in the early 1800s, publications on
MBC have steadily continued to increase from one or
two each year to a peak of 68 publications in 2014. Data
was obtained from PubMed using the search term “male
breast cancer” in titles and abstracts from January 1st to
December 31st, 2014 (search performed December
22nd, 2014).
According to the most recent estimates by The Inter-
national Agency for Research on Cancer, a division of
the World Health Organization, the global incidence of
MBC stands at nearly 8,000 cases. For Europe, this
equates to 3,750 cases of MBC [2]. In the US, the esti-
mated number of cases in 2014 was expected to be 2,360,
while the lifetime risk of men getting breast cancer is 1 in
1,000 [3]. These figures are significantly lower (<1 %) than
the incidence of breast cancer in women, which represents
11.6 % of the global cancer incidence in 2014 [4], with* Correspondence: v.speirs@leeds.ac.uk
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with breast cancer annually in the US and Europe, respect-
ively [5, 6]. Men typically present, on average, 5 years later
than women, commonly in the seventh decade [7–9].Increasing incidence of male breast cancer (MBC)
Studies suggest that MBC incidence is rising [10–14]. A
large population-based study of 2,537 men with breast
cancer, analysed from the National Cancer Institute’s
Surveillance, Epidemiology and End Results (SEER) data-
base, reported that over a 25 year period (1973–1998)
the incidence of MBC increased significantly from 0.86
to 1.08 per 100,000 population in the US [15], with
higher incidence in black than white men [16]. We have
confirmed this in a more recent interrogation of the
SEER dataset (Fig. 1) [17]. In terms of race, the rates of
breast cancer are higher in black than white men while
the reverse is true in female breast cancer (FBC) patients
(Fig. 2). It should be noted from Fig. 2 that the incidence
rates of FBC appear to plateau, which may be attributed
to introduction of breast screening programs in the fe-
male population [18]. The higher rate of MBC observed
in black men is at least partly due to more advanced
disease presentation; studies have reported that a higher
number of black MBC patients present with larger tumoursss article distributed under the terms of the Creative Commons Attribution
by/4.0), which permits unrestricted use, distribution, and reproduction in any
ly credited. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
Fig. 1 Age-adjusted increasing incidence rates in white men over a 36 year period (Diamonds), with the incidence rates in black men over the
same time period overlaid (Squares). Data obtained and graphs generated from SEER using the Fast Stats Registry, National Cancer Institute
Fig. 2 Age-adjusted increasing incidence rates in white women over a 36 year period (Diamonds), with the incidence rates of black women over
the same time period overlaid (Squares). Data obtained and graphs generated from SEER using the Fast Stats Registry, National Cancer Institute
Humphries et al. BMC Medicine  (2015) 13:134 Page 2 of 9
Humphries et al. BMC Medicine  (2015) 13:134 Page 3 of 9of higher grade, lymph node metastases, and lacking in
hormone receptor expression, compared to white men
[19]. Such racial disparity may be associated with bio-
logical/genetic predispositions or socioeconomic factors
such as access to health care [16, 20, 21], highlighted
recently by work addressing disparities between black
and white men with early stage MBC [22].
While at first glance data from the UK (Cancer Research
UK) suggests no change in age-standardised incidence
from 1975–2011 [23], when grouped into decades, there is
a rise in the average age-standardised incidence of 0.79/
100,000 population in the 1975–1980 to 0.85/100,000
from 1990–2011 (Fig. 3).
It is possible that perceived increases in MBC inci-
dence may simply reflect increased disease detection.
Men are generally more health conscious than in previ-
ous generations, perhaps aided by increased awareness
of breast cancer in general, and public education in
MBC specifically, for example, through the John W Nick
Foundation [24]; part of their mission statement is “to
educate the world about the risk of breast cancer in
men”. Such campaigns may encourage men to present
to a physician with breast-related symptoms, potentially
increasing detection rates. Age, the single biggest risk
factor for breast cancer, should also be considered; as
an ageing population, increased MBC may well parallel
increased longevity. However, increase in MBC is also
reflected in age-standardised rates [15], which probably
negates this argument.
Obesity
One of the most worrying global public health issues
is the exponential rise in the number of overweight
and obese people, which in a comprehensive study of
1,769 reports from 188 countries showed a rise fromFig. 3 Average age-standardisation incidence rates (ASR) of male
breast cancer in the UK per 100,000 in the 1970s and 80s vs 1990–2011.
Average rate in the 1970s and 1980s was 0.79/100,000, while the average
rate in 1990 to 2011 was 0.85/100,000. Figure generated from raw data
taken from Cancer Research UK [21]857 million in 1980 to 2.1 billion in 2013 [25] (Fig. 4);
this has been described as “a global pandemic” [26, 27]. A
key fact from these data is that, over this time period,
more men than women were classified as overweight or
obese in developed countries, whereas the opposite was
true in developing countries [25]. The prevalence of over-
weight and obesity (overweight = body mass index (BMI,
calculated as weight in kilograms divided by the square of
height in meters) ≥25; obese = BMI ≥30) were highest in
the World Health Organization regions of the Americas
(62 % for overweight in both sexes, and 26 % for obesity);
65 % of the world’s population live in countries where
overweight and obesity kills more people than under-
weight [28]. This trend shows no signs of reversing or
even slowing as worldwide childhood obesity prevalence
in 2010 was 6.7 %. Worryingly, in the United States, 20 %
of children are categorised as obese [29].
Obesity and cancer
It has long been known that obesity and the risk of cancer
are linked. The International Agency for Research on
Cancer and the World Cancer Research Fund reports
show that common cancers in obese people are pre-
dominantly endometrial, esophageal adenocarcinoma,
colorectal, postmenopausal breast, prostate, and renal
[30, 31]. Recent data from the US provided evidence
that the number of white men considered overweight
or obese was higher than that of black men (BMI ≥25).
However, when higher BMI was observed (BMI ≥30)
the converse was true. Furthermore, there were 55 %
more extremely obese black than white males (BMI ≥40)
[32]. Interestingly, this increase in male obesity in devel-
oped countries seems to mirror an increase in incidence
of MBC [25, 33, 34]. This is also reflected by comparing
data in Figs. 1 and 4, where respective increases in theFig. 4 Increase in the global prevalence of obesity in males and
females ≥20 years old from 1980–2013. Image adapted using data
from [25]
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In women, there is substantial and convincing evidence
that weight gain at or around the menopause is a strong
risk factor for breast cancer [35–39]. New evidence has
emphasised this wherein obesity constituted an independ-
ent, adverse prognostic factor in node-positive FBC; this
was particularly significant in estrogen receptor positive
(ER+) postmenopausal women [40]. Furthermore, increas-
ing incidence of FBC is seen in developing countries where
Western lifestyles are increasingly adopted [41]. It should
be noted that, while obesity is a risk for FBC, other known
risk factors include changes in reproductive practices,
duration of breast feeding, and administration of hormone
replacement therapy [19]. As these do not apply to men,
could the parallel rises of obesity and MBC incidence
be linked? The case has been made that the increased
incidence is simply a pseudo observation due to an in-
crease in detection [42], which may well be true; how-
ever, without comprehensive epidemiological studies
the rationale for the increased MBC incidence can only
be speculated.
Known risk factors for male breast cancer (MBC)
Risk factors associated with MBC include age, underlying
genetics, including Klinefelter syndrome and BRCA2
mutations, radiation exposure, high estrogen levels, and
liver cirrhosis as a result of excess alcohol consumption
[7, 13–15, 33, 43–47]. However, a more recent publication
has cast doubt on this latter association [48]. Gynecomastia
is a relatively common benign enlargement of the male
breast affecting an estimated 40–65 % of males [49], with
some studies considering this a risk factor for MBC devel-
opment [33] by as much as 10-fold [14]. Interestingly,
gynecomastia is often associated with male obesity [50, 51].
Though not officially recognised as a risk factor for MBC,
obesity has been highlighted by several studies as being
significantly associated with MBC [14, 47, 52]. When
one considers that adipose tissue contains aromatase, which
converts testosterone to estrogen, increased levels of estro-
gen could produce an environment for cancer initiation in
male breast tissue. Furthermore, conversion of testosterone
to estradiol by aromatase in adipose tissue suppresses
the release of luteinizing hormone, in turn leading to a
reduction in testosterone production [53, 54]. As a result,
estrogen levels are significantly higher in older men
than post-menopausal women [55]. Adipose tissue is a
recognised site for the production of steroid hormones.
Aromatase is one of several enzymes found in adipose
tissue and is involved in estrogen biosynthesis by con-
verting testosterone to estrogen (Fig. 5). In addition to
aromatase, other steroid-metabolising enzymes, including
17β-hydroxysteroid dehydrogenases, play a role in increas-
ing local estradiol concentrations [56]. Notably, localization
of both aromatase and 17β-hydroxysteroid dehydrogenasetype 1 has been observed in MBC [57]. Adipose tissues are
also recognised for their ability to secrete other factors,
such as cytokines, which can enhance local estrogen
biosynthesis that may exert local and/or systemic ef-
fects [58–64]. Recent data from the Male Breast Cancer
Pooling Project supports the importance of estrogen in
MBC etiology [65].
In the obese male, excess adipose tissue provides an
environment conducive to increased estrogen production.
Indeed, obese men produce as high as 2-fold more estro-
gen than men with average BMI [66] and males with very
high BMI (≥35) show markedly decreased testosterone
levels and increased concentrations of estradiol in blood
plasma [15, 67–71]. Thus, weight increase coupled with
the declining levels of hormones in the ageing male could
provide a hormone environment which helps promote the
genesis of MBC in obese men. In addition, a study by
Brinton et al. [14], which included results from the Male
Breast Cancer Pooling Project, provided evidence from
over 2,400 patients from 10 cohort studies indicating that
obesity was a positive risk factor for MBC; the authors
observed a 30 % increased risk in MBC from obesity.
This increased risk was in agreement with studies in
post-menopausal FBC demonstrating a similar increased
risk in cancer [72–74].Survival rates and treatment for male breast
cancer (MBC)
MBC survival rates are generally assumed to be lower
than in FBC, probably as a result of later diagnosis and
the assumption that treatments developed through trials
for FBC patients will perform equally well in men [75].
A study of over 13,000 men and almost 1.5 million
women with breast cancer were reviewed over a 9 year
period and showed 5 year survival rates of 74 % for men
and 83 % for women [76]. The stage at diagnosis was a
determining factor in survival rates for men compared
to women. Latter stage diagnosis was more comparable,
with 5 year survival in men at 16 % and women at 19 %.
[76]. A European study including almost 500,000 women
and over 2,500 men concluded that survival was worse
in men than women until adjusting for age, stage and
treatment, whereby the opposite was true [19]. This is in
agreement with other smaller studies [8, 77, 34]. Add-
itionally, time to diagnosis is negatively impacted by the
presence of obesity [78–80]. This is due, but not limited
to, difficulties in self-detection and possible embarrassment
in seeking medical consultation due to excess weight.
Further, obese patients are more likely to postpone
clinical appointments for 3 months following first
symptom occurrence [81]. Furthermore, obese patients
undergo MRI and ultrasound less often when compared
to those within a normal weight range [82]. All of the
Fig. 5 Pathways of steroid hormone metabolism in adipose tissue. Bold boxes highlight steroid hormones. Italics denote enzymes with
arrows indicating direction of metabolism. Aromatase enzyme highlighted in bold italics. 3β-HSD1, 3β-hydroxysteroid dehydrogenase
type 1; 17β-HSD2, 17β-hydroxysteroid dehydrogenase type 2; 17β-HSD3, 17β-hydroxysteroid dehydrogenase type 3; 17β-HSD5, 17β-hydroxysteroid
dehydrogenase type 5; 17β-HSD12, 17β-hydroxysteroid dehydrogenase type 12. Image was compiled by the author by drawing on information
from [56, 116, 117]
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tion which could impact survival.
The current standard of care for MBC patients is tamoxi-
fen [83–87]. The case could be made that, when obese
males present with MBC, aromatase inhibitors (AIs) should
be advocated. Indeed, some studies have encouraged this
for ER+ MBC patients in combination with tamoxifen [88].
However, this contradicts data from the ATAC (Arimidex,
Tamoxifen, Alone or in Combination) trial, which com-
pared the efficacy of AIs with tamoxifen, alone or in
combination [89], where the combination treatment
arm was closed after an initial analyses at 33 and 47
months of follow-up due to low efficacy [89, 90]. Granted,
the ATAC trial was female-only but with growing evidence
of biological differences between MBC and FBC [57,
91–95], the outcome may well be different in men.
However, there are difficulties in accruing for a gender-
specific trial, as highlighted by the withdrawal of a phase II
study (SWOG-S0511) due to poor accrual of MBC pa-
tients (ClinicalTrials.gov. Trial record: NCT00217659).
Nevertheless, analysis of 257 hormone-receptor-positiveGerman MBC patients treated with tamoxifen (n = 207)
or AIs (n = 50) showed the overall survival was signifi-
cantly better after adjuvant treatment with tamoxifen
compared to AI [96].
No clinical studies we are aware of have reported on
the treatment of obese MBC patients with tamoxifen
and AIs. Obesity in MBC patients should be considered
in the context of treatment. Treatment with AIs alone
have been shown to increase LH and FSH levels, which
may be deleterious due to increased substrate for aroma-
tisation in some MBC patients and further exacerbate the
situation [97–100]. It has been hypothesised that introdu-
cing a gonadotropin-releasing hormone analogue with
AIs, should tumour progression be seen, could counteract
the activity of the hormonal feedback loop [88].
Additionally, functional single nucleotide polymorphisms
(SNPs) exist in the aromatase gene that can improve how
breast cancer patients respond to AIs. These alterations
in the wild-type and variant sequences result in different
DNA protein binding capabilities and displayed different
transcriptional activity, resulting in atypical estrogen
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that altered estrogen levels can be modified by changes in
BMI in patients with these SNPs in aromatase [102].
These data highlight the need for further experimental
studies focusing on the biological consequences of obesity
and how this may impact on MBC treatment.
It is pertinent at this juncture to bring to light the
connection between cholesterol and its oxysterol metab-
olite 27-hydroxycholesterol (27HC) in the context of
obesity. 27HC is a recognised selective ER modulator
(SERM) and was the first endogenous ligand demon-
strated as having SERM activity [103]. The conversion of
27HC from the hydroxylation of cholesterol is achieved
by the cytochrome p450 enzyme, CYP27A1 [104]. The
ligand binding of 27HC to ER in ER+ breast cancer has
been shown to induce cell proliferation [105, 106]. As
MBC is overwhelmingly ER+ it follows logically that
patients with higher 27HC provide a favourable growth
environment for tumour development. Circulating levels
of 27HC correlate with cholesterol levels; however, in
the obese patient, cholesterol is often much higher and
consequently an increase in 27HC is reported [107].
The consequence for the obese male is that increased
27HC levels, as a direct consequence of higher choles-
terol, could contribute to the development of MBC via
the mitogenic signalling of 27HC in the male breast.
Conclusions
While the case for linking obesity to MBC is strong, a
number of other contributing factors should be discussed.
Changes in the Western diet over the past several decades
may not only have shifted the average body composition
towards a more obese/overweight state [108], but also
changed the dietary composition towards a high intake of
refined carbohydrates, added sugars, fats, and animal-
source foods. Increased body awareness may result in earl-
ier visits to GPs than in previous generations to investigate
a problem, which will contribute to increased detection
rates. Exposure to so-called environmental oestrogens via
diet, household products, perfumes and deodorants are
considered by some as risk factors for breast cancer devel-
opment as collectively, prolonged exposure to low doses
of these compounds could provide a significant estrogenic
stimulus to target tissues [109–112]. However, there are
no substantive data to support this and this would not be
gender-specific.
Based on current evidence, we propose that the incidence
trends of both MBC and obesity are inextricably linked
and, as others have postulated [14, 47, 52], obesity should
be considered as a risk factor for MBC in the same way this
has recently been proposed for prostate cancer [113]. When
considering treatment, a contextual perspective should
be adopted with the atypical microenvironment, created
and exacerbated by obesity, taken into account. Obesity isrecognised as a preventable condition and sufficient
weight loss has been shown to flip the ratio of hormones to
normal physiological levels in obese men (BMI ≥30) [114,
115]. Peripheral aromatisation of androgens in adipose tis-
sue of obese men could provide a hormonal milieu which
encourages tumour development. While the risks of MBC
from obesity have not been quantified, we propose that
men at risk from MBC, e.g., those with BRCA2 mutations
or suffering from Klinefelter syndrome, should be made
aware of the relative risk between MBC and obesity to take
pre-emptive measures to reduce this risk.
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